Researchers identify a test to target cancer drug

October 26, 2017

Doctors are developing a more personalised approach to the treatment of bowel cancer, thanks to research which has found a way of screening tumours for their susceptibility to drug therapy.

Delivering 'customised care' is important because every cancer is different - so may respond differently to treatment.

The cancer drug panitumumab is one option for patients with advanced bowel cancer, and doctors already use a genetic test called RAS to select patients who may be helped by it. But even using the RAS test, although panitumumab can control symptoms and extend life for some patients, for others it is ineffective and may cause unpleasant side-effects.

The problem is that currently doctors do not know in advance who is going to benefit and who is not.

Now researchers at the University of Leeds, collaborating with scientists at Duke University in North Carolina in the USA, have identified a protein called HER3 in tumours which could help predict if treatment with the drug will be effective.

They have found that a patient whose cancer has a high level of HER3 are likely to benefit from the drug. On the other hand, a patient whose cancer lacks the protein may get no benefit and still suffer the drug's side-effects.

Writing in the journal JAMA Oncology, the researchers report that patients with a raised level of HER3 saw their tumour shrink or stabilise for - on average - an extra four months if treated with panitumumab. In patients with low HER3 levels, panitumumab had no effect.

Last year, the same research team published a paper reporting that the presence of other proteins, called ligands, can also help predict who will benefit from panitumumab. An analysis in the current paper combined information from both HER3 and ligands, and showed that panitumumab performs best in the 20% of patients whose cancers have high levels of both these markers.

Dr Jenny Seligmann, a CRUK Clinical Trials Fellow at the University of Leeds, lead author of the paper said: "HER3 appears to be a helpful test - in about half the patients who might otherwise receive panitumumab it shows that the drug would be ineffective or even harmful, and these patients could instead be offered another treatment option.

"And if we combine both indicators - HER3 and ligands - we can identify the 20 per cent of patients for whom panitumumab is the most effective in prolonging cancer control, making it a compelling treatment choice for them".

The study used tumour samples donated for research by 308 patients from all over the UK who, between 2006 and 2010, took part in a trial testing the addition of panitumumab to their cancer treatment.

The team was able to see how patients had responded to the drug and then went back and tested their stored tumour samples for levels of the ligands and HER3 proteins.

Professor Matt Seymour, who led the research team, said: "These findings are important in that we are now closer to developing a test to identify patients for whom panitumumab is a powerful and effective therapy.

"We are hugely grateful to the patients who participated in the trial and gave permission for us to use their cancer samples to perform this research.

"More work still needs to be done before the test can be offered to patients routinely. We need to confirm our results in other trials, and to work out how best to test for these proteins rapidly and reliably, so that doctors can be advised whether to offer the drug."

The research was funded by Cancer Research UK.

The research adds to the growing picture of the importance of personalised medicine in cancer care. Through a clearer understanding of some of the biochemical mechanisms involved in an individual's cancer, doctors are better able to target various therapies. Bowel cancer is the fourth most common form of cancer and around 110 new cases are diagnosed every day in the UK, according to statistics from Cancer Research UK.

Advanced bowel cancer is seen when the disease spreads from the bowel to another part of the body. At this stage the disease cannot be stopped but successful treatment can slow its progress.
-end-
Notes to Editors

For further information please contact David Lewis in the University press office on 0113 343 8059 or by email d.lewis@leeds.ac.uk

University of Leeds The University of Leeds is one of the largest higher education institutions in the UK, with more than 33,000 students from more than 150 different countries, and a member of the Russell Group of research-intensive universities.

We are a top ten university for research and impact power in the UK, according to the 2014 Research Excellence Framework, and are in the top 100 for academic reputation in the QS World University Rankings 2018. Additionally, the University was awarded a Gold rating by the Government's Teaching Excellence Framework in 2017, recognising its 'consistently outstanding' teaching and learning provision. Twenty-four of our academics have been awarded National Teaching Fellowships - more than any other institution in England, Northern Ireland and Wales - reflecting the excellence of our teaching. http://www.leeds.ac.uk

Follow University of Leeds or tag us in to coverage

Twitter
Facebook
LinkedIn
Instagram

University of Leeds

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.